Extracellular volume quantification using synthetic haematocrit assessed from native and post-contrast longitudinal relaxation T1 times of a blood pool

Table 1 Characteristics of the patient groups: genetic carriers of Duchenne muscular dystrophy, patients after anthracycline treatment, heart transplant, chronic obstructive pulmonary disease and controls

Primary diagnosis	Number of patients	Age	Female	Mean laboratory Htc	Mean T1 blood relaxation time—native	Mean T1 blood relaxation time—post-contrast
Overall	139	35.42 ± 15.97	76 (54.7%)	0.41 ± 0.04	1545.78 ± 84.24	229.76 ± 27.03
DMD carriers	40	37.93 ± 11.85	40 (100%)	0.4 ± 0.03	1560.33 ± 79.66	223.92 ± 24.64
Patients after anthracycline treatment	71	25.99 ± 5	26 (36.6%)	0.42 ± 0.04	1534 ± 80.12	230.9 ± 29.02
HT	8	53.63 ± 13.51	2 (25%)	0.4 ± 0.08	1563.5 ± 104.27	234 ± 26.46
COPD	15	67.33 ± 8.5	5 (33.3%)	0.42 ± 0.04	1566.13 ± 70.54	235.67 ± 19.72
Controls	5	24.4 ± 2.58	3 (60%)	0.44 ± 0.04	1496.8 ± 69.15	235.8 ± 24.21

Values represent the number of patients or the median ± standard deviation
Htc = haematocrit, DMD carriers = genetic carriers of Duchenne muscular dystrophy, HT = heart transplant, COPD = chronic obstructive pulmonary disease

ISSN: 1471-2261